# 2026年EANM青年科學家網絡獎旨在加速前列腺癌α放射配體療法（α-RLT）的創新研究。

*biotech · news · 2026-02-24 · News-Medical.net*

## Key points

- 2026年首屆EANM青年科學家網絡獎現正接受針對α-RLT研究的申請。
- 該獎項專注於前列腺癌的α放射配體療法研究。
- 得獎者將分別獲得白金獎（40,000歐元）、黃金獎（20,000歐元）或白銀獎（10,000歐元）。
- 申請資格限於在EANM會員國內，取得終端學位不超過10年的研究人員。

Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer. Winners will be recognized across three award categories: Platinum (40,000 euros), Gold (20,000 euros), and Silver (10,000 euros) awards. Alpha radioligand therapy is rapidly emerging as a transformative frontier in precision oncology, and we strongly believe in the talent of researchers at the beginning of their careers in this field. This award was designed to nurture their growth by pairing research excellence with structured training, mentorship, and collaborative networking opportunities." Paola Anna Erba, EANM President Shaping the future of prostate cancer EANM invites applications from early career researchers - PhD candidates, postdoctoral fellows, junior faculty, and clinicians-in-training - who are within 10 years of their terminal degree and affiliated with an institution in an EANM member country.

**Companies:** Novartis

[Read the full story on News-Medical.net](https://www.news-medical.net/news/20260223/New-EANM-award-supports-alpha-radioligand-therapy-research.aspx)

---

Canonical: https://newsio.io/zh-TW/n/1b1926f0-b1ca-4033-afdb-a4ca06c2d454/2026eanm-rlt
Summarized by Newsio from News-Medical.net. https://newsio.io/how-it-works